Ketamine Treatment Plans for Chronic Conditions
Launched by RIVER FOUNDATION · Sep 7, 2023
Trial Information
Current as of June 18, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how effective different ways of using ketamine are for treating chronic conditions like chronic pain, depression, anxiety, and other long-term health issues. Ketamine is a medication that is often used off-label, which means it’s used in ways not officially approved by health authorities. The study wants to understand how well ketamine works for people who are already receiving this treatment for their chronic conditions.
If you or a loved one are between the ages of 65 and 74 and have a diagnosed chronic condition, you might be eligible to participate in this study. However, healthy individuals without a chronic condition cannot join. Participants can expect to receive ketamine as part of their treatment plan and will help researchers learn more about its effectiveness. It’s important to know that this study is currently recruiting, so there is an opportunity to take part in this important research aimed at improving care for chronic conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Must have an identifiable chronic condition.
- Exclusion Criteria:
- • Healthy population
About River Foundation
River Foundation is a dedicated clinical research organization committed to advancing healthcare through innovative research and development. With a focus on fostering partnerships in the medical community, River Foundation conducts rigorous clinical trials aimed at evaluating new therapies and treatment modalities. The organization prioritizes patient safety and ethical standards while striving to enhance the quality of life for individuals affected by various health conditions. Through its collaborative approach and commitment to scientific integrity, River Foundation plays a pivotal role in translating research findings into meaningful healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Helena, Montana, United States
Patients applied
Trial Officials
Edward Lesofski, MS
Study Director
RIVER Foundation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported